Aditya Birla Sun Life Pharma & Healthcare Fund
An open ended equity scheme investing in Pharma and Healthcare Services Sector
February 2026
| Equity Scheme |  |
 |
 |
 |
An open ended equity scheme investing in Pharma and Healthcare Services Sector
February 2026
| Equity Scheme | |
|
|
|
| Investment Objective | |
| The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved | |
| Fund Category: Thematic (Equity) | |
 |
|
| Fund Snapshot | |
| Date of Allotment : Jul 11, 2019 | |
| Benchmark: BSE Healthcare TRI | |
| Fund Manager -Mr. Dhaval Shah Managing the Fund Since: July 11, 2019 Experience in Managing the Fund: 6.6 Years |
|
| SIP: Daily/Weekly/Monthly: Minimum ₹ 100/-and in multiples of ₹ 1/- thereafter |
|
| Application Amount for fresh subscription: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Minimum Additional Investment: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | NIL |
| Exit Load: | For redemption/switch-out of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |
| Count of Securities:36 | |
| AUM as on February 27, 2026 (in ₹Crore) | |
| Month End AUM | 854.04 |
| Monthly Average AUM | 836.33 |
| Total Expense Ratio (TER) | |
| Regular | 2.30% |
| Direct | 1.02% |
| Including additional expenses and goods and service tax on management fees. | |
| NAV as on February 27, 2026 | |
| Regular Growth | 31.22 |
| Regular IDCW$ | 20.62 |
| Direct Growth | 34.56 |
| Direct IDCW$ | 22.47 |
| $Income Distribution cum capital withdrawal | |
| Valuation Parameters | |
| Average P/E | 39.18 |
| Average P/BV | 6.46 |
| Average Dividend Yield | 0.67% |
| Top 10 Sectoral Contribution (in %) |
 |
| Market Capitalisation |
 |
| Volatility Measures | |
| Portfolio Turnover | 0.26 |
| Standard Deviation | 15.75% |
| Sharpe Ratio | 1.22 |
| Beta | 0.94 |
| Treynor Ratio | 0.21 |
| Information Ratio | -0.58 |
| Rating Profile of Portfolio |  |
| Sector/Issuer Name | % of Net AUM |
Equity & Equity Related |
|
Pharmaceuticals & Biotechnology |
76.60 % |
• Sun Pharmaceutical Industries Limited |
13.34 % |
• Torrent Pharmaceuticals Limited |
5.20 % |
• J.B. Chemicals & Pharmaceuticals Limited |
4.99 % |
• Ajanta Pharmaceuticals Limited |
4.53 % |
• Lupin Limited |
4.21 % |
• Aurobindo Pharma Limited |
4.16 % |
• Abbott India Limited |
4.02 % |
• IPCA Laboratories Limited |
3.94 % |
Cipla Limited |
3.59 % |
Emcure Pharmaceuticals Ltd |
3.03 % |
Mankind Pharma Ltd |
2.65 % |
Alkem Laboratories Limited |
2.31 % |
Shilpa Medicare Ltd |
2.20 % |
CORONA Remedies Ltd |
2.17 % |
SAI Life Sciences Ltd |
2.16 % |
Divi''s Laboratories Limited |
1.95 % |
Dr. Reddys Laboratories Limited |
1.49 % |
Procter & Gamble Health Limited |
1.46 % |
ALEMBIC PHARMACEUTICALS LIMITED |
1.34 % |
Biocon Limited |
1.24 % |
SANOFI CONSUMER HEALTHCARE |
1.24 % |
Jubilant Pharmova Ltd |
1.19 % |
Pfizer Limited |
1.08 % |
Gland Pharma Limited |
1.07 % |
Piramal Pharma Ltd |
1.06 % |
GlaxoSmithKline Pharmaceuticals Limited |
0.99 % |
Healthcare Services |
19.90 % |
• Apollo Hospitals Enterprise Limited |
7.78 % |
• Fortis Healthcare Limited |
4.17 % |
Jupiter Life Line Hospitals Ltd |
1.94 % |
Thyrocare Technologies Limited |
1.63 % |
METROPOLIS HEALTHCARE LIMITED |
1.50 % |
Suraksha Diagnostic Ltd |
1.06 % |
Vijaya Diagnostic Centre Limited |
0.92 % |
Max Healthcare Institute Limited |
0.90 % |
Insurance |
1.14 % |
Medi Assist Healthcare Services Ltd |
1.14 % |
Chemicals & Petrochemicals |
0.81 % |
Vinati Organics Limited |
0.81 % |
Net Cash and Cash Equivalent |
1.55 % |
Grand Total |
100.00% |
Miscellaneous includes securities with exposure of less than 0.01%
| Scheme Name | |
| Aditya Birla Sun Life Pharma & Healthcare Fund An open ended equity scheme investing in Pharma and Healthcare Services Sector |
|
| This product is suitable for investors who are seeking*: | |
|
|
Risk-o-meter  |
Benchmark Risk-o-meter BSE Healthcare TRI  |
| *Investors should consult their financial advisors if in doubt whether the product is suitable for them. | |